Literature DB >> 7696228

External beam radiotherapy for retinoblastoma: II. Lens sparing technique.

N M Toma1, J L Hungerford, P N Plowman, J E Kingston, D Doughty.   

Abstract

A retrospective analysis is presented of the results of external beam radiotherapy for retinoblastoma utilising an accurate lens sparing technique. Local tumour control has been assessed in a consecutive series of 67 eyes in 53 children all of whom received external beam radiotherapy as the primary treatment of retinoblastoma. Follow up ranged from 12 to 82 months (median 35 months) with 76% of the children followed for more than 2 years. Tumour control rates have been analysed with respect to the Reese-Ellsworth classification. The role of adjuvant and salvage focal therapy is emphasised. Following lens sparing radiotherapy with prior adjuvant treatment of anterior tumours, where appropriate, the overall ocular cure rate was 72%. With salvage therapy of persistent, recurrent, or new tumours, 93% of eyes could be preserved in this series which includes mainly eyes classified in Reese-Ellsworth groups I-III. These results compare favourably with those of whole eye external beam radiotherapy for comparable tumours, and with those of lens and anterior segment sparing using other techniques. They were achieved without the ocular morbidity associated with whole eye external beam radiotherapy.

Entities:  

Mesh:

Year:  1995        PMID: 7696228      PMCID: PMC505039          DOI: 10.1136/bjo.79.2.112

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  21 in total

1.  The evaluation and current concept of retinoblastoma therapy.

Authors:  A B REESE; R M ELLSWORTH
Journal:  Trans Am Acad Ophthalmol Otolaryngol       Date:  1963 Mar-Apr

2.  The conservative treatment of retinoblastoma.

Authors:  H B STALLARD
Journal:  Trans Ophthalmol Soc U K       Date:  1962

3.  A clinical study of radiation cataracts and the relationship to dose.

Authors:  G R MERRIAM; E F FOCHT
Journal:  Am J Roentgenol Radium Ther Nucl Med       Date:  1957-05

4.  New and recurrent tumor foci following local treatment as well as external beam radiation in eyes of patients with hereditary retinoblastoma.

Authors:  E P Messmer; W Sauerwein; T Heinrich; W Höpping; D Klueter-Reckmann; N Bornfeld; H Sack; M Förster; W Havers
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1990       Impact factor: 3.117

5.  Ocular complications after therapeutic irradiation.

Authors:  P A Macfaul; M A Bedford
Journal:  Br J Ophthalmol       Date:  1970-04       Impact factor: 4.638

6.  Radiation therapy for retinoblastoma: comparison of results with lens-sparing versus lateral beam techniques.

Authors:  B McCormick; R Ellsworth; D Abramson; B Haik; M Tome; E Grabowski; T LoSasso
Journal:  Int J Radiat Oncol Biol Phys       Date:  1988-09       Impact factor: 7.038

7.  The treatment of advanced retinoblastoma by means of external irradiation combined with chemotherapy.

Authors:  D B Skeggs; I G Williams
Journal:  Clin Radiol       Date:  1966-04       Impact factor: 2.350

8.  Stage-related combined modality treatment of retinoblastoma. Results of a prospective study.

Authors:  C Howarth; D Meyer; H O Hustu; W W Johnson; E Shanks; C Pratt
Journal:  Cancer       Date:  1980-03-01       Impact factor: 6.860

9.  External beam irradiation for retinoblastoma: patterns of failure and dose-response analysis.

Authors:  R L Foote; B R Garretson; P J Schomberg; S J Buskirk; D M Robertson; J D Earle
Journal:  Int J Radiat Oncol Biol Phys       Date:  1989-03       Impact factor: 7.038

10.  Treatment of retinoblastoma by precision megavoltage radiation therapy.

Authors:  J Schipper; K E Tan; H A van Peperzeel
Journal:  Radiother Oncol       Date:  1985-02       Impact factor: 6.280

View more
  13 in total

Review 1.  Chemotherapy for retinoblastoma: a current topic.

Authors:  P T Finger; G Czechonska; H Demirci; A Rausen
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

2.  Radiotherapy in ophthalmology : 2004 Jules Gonin lecture of the Retina Research Foundation.

Authors:  Leonidas Zografos
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-07       Impact factor: 3.117

3.  Lens Dose-Response Prediction Modeling and Cataract Incidence in Patients With Retinoblastoma After Lens-Sparing or Whole-Eye Radiation Therapy.

Authors:  Steven M Nguyen; Julian Sison; Marjorie Jones; Jesse L Berry; Jonathan W Kim; A Linn Murphree; Vanessa Salinas; Arthur J Olch; Eric L Chang; Kenneth K Wong
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-12-08       Impact factor: 7.038

4.  T1 Gd-enhanced compared with CISS sequences in retinoblastoma: superiority of T1 sequences in evaluation of tumour extension.

Authors:  Elke R Gizewski; Isabel Wanke; Christine Jurklies; Ali-Riza Güngör; Michael Forsting
Journal:  Neuroradiology       Date:  2005-01-14       Impact factor: 2.804

Review 5.  [Retinoblastoma].

Authors:  N Bornfeld; A Schüler; R Bölöni; C Jurklies; R Wieland; W Sauerwein; D Lohmann
Journal:  Ophthalmologe       Date:  2006-01       Impact factor: 1.059

6.  External beam radiotherapy for retinoblastoma: I. Whole eye technique.

Authors:  J L Hungerford; N M Toma; P N Plowman; J E Kingston
Journal:  Br J Ophthalmol       Date:  1995-02       Impact factor: 4.638

7.  Retinoblastoma major review with updates on Middle East management protocols.

Authors:  Ihab Saad Othman
Journal:  Saudi J Ophthalmol       Date:  2012-04

8.  Globe conserving treatment of the only eye in bilateral retinoblastoma.

Authors:  V Lee; J L Hungerford; C Bunce; F Ahmed; J E Kingston; P N Plowman
Journal:  Br J Ophthalmol       Date:  2003-11       Impact factor: 4.638

9.  Treatment of retinoblastoma: current status and future perspectives.

Authors:  Carlos Rodriguez-Galindo; Guillermo L Chantada; Barrett G Haik; Matthew W Wilson
Journal:  Curr Treat Options Neurol       Date:  2007-07       Impact factor: 3.598

Review 10.  Radiotherapy for ocular tumours.

Authors:  C Stannard; W Sauerwein; G Maree; K Lecuona
Journal:  Eye (Lond)       Date:  2012-11-23       Impact factor: 3.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.